A real-world evaluation of the clinical benefits of improved sound processor technology among Chinese cochlear implant users: A focus on Cochlear Nucleus 7
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307044 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Xiaocong Deng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Hainan Cancer Hospital, Haikou, Hainan, China. Hauptthemen laut MEDLINE: Cochlear Implants, Speech Perception. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cochlear Medical Device Co. Ltd., Beijing, China, Cochlear Asia Pacific.
Abstract (Originalsprache)
Real-world evidence is increasingly used to support clinical and regulatory decisions globally and may be a useful tool to study the unique needs of cochlear implant users in China. The ability to recognize and understand speech in noise is critical for cochlear implant users, however, this remains a challenge in everyday settings with fluctuating competing noise levels. The Cochlear™ Sound Processor, Nucleus ® 7 (CP1000), includes Forward Focus, a spatial noise algorithm aimed to improve speech-in-noise performance, and Made for iPhone/iPod/iPad functionality. We conducted a prospective, single-center, open-label, within-participant, real-world evidence investigation in participants with cochlear implants. The primary objective of this study, conducted in China, was to compare speech perception in spatially separated dynamic noise with the Nucleus 7 to the recipients’ current older Cochlear Sound Processor, including the Freedom and Nucleus 5 sound processors. A follow-up study monitored participants from the initial study up to 12-months post the fitting of their Nucleus 7 and investigated hearing ability, satisfaction, and usability of the device via a questionnaire. Forty participants were included in the initial study (age-range 3 to 49 years) and 29 continued to the follow-up study (age-range 5 to 28 years). The participants were heterogeneous in terms of age, cochlear implant experience, and duration of hearing loss. Nucleus 7 significantly improved participant speech recognition performance in noise by 7.54 dB when compared with the participants’ current older sound processor (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Head and Neck Surgery, Hainan Cancer Hospital, Haikou, Hainan, China.
- Medical Affair Department, Cochlear Great China, Beijing, China.
- Department of Otolaryngology and Head and Neck Surgery, Boao Super Hospital, Qionghai, China.
ORCID-Profile: Jin Zhang
Förderung
- Cochlear Medical Device Co. Ltd., Beijing, China
- Cochlear Asia Pacific
Zitieren
APA
Deng, X., Wu, C., Wu, L., Lu, J., & Zhang, J. (2024). A real-world evaluation of the clinical benefits of improved sound processor technology among Chinese cochlear implant users: A focus on Cochlear Nucleus 7. PLOS ONE. https://doi.org/10.1371/journal.pone.0307044
Vancouver
Deng X, Wu C, Wu L, Lu J, Zhang J. A real-world evaluation of the clinical benefits of improved sound processor technology among Chinese cochlear implant users: A focus on Cochlear Nucleus 7. PLOS ONE. 2024. doi:10.1371/journal.pone.0307044
BibTeX
@article{Deng2024,
author = {Deng, Xiaocong and Wu, Chenjiong and Wu, Lin and Lu, Jiyun and Zhang, Jin},
title = {A real-world evaluation of the clinical benefits of improved sound processor technology among Chinese cochlear implant users: A focus on Cochlear Nucleus 7},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307044}
}
EUVIMED